Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HS-10522 Tablets in Healthy Chinese Participants and Chinese Participants With Mild Hypertension

NCT07609875 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07609875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07609875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HS-10522 Tablets in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
February 3, 2027
Enrollment
88 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult, hypertension